Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: A meta-analysis

Blood

Volumn 120, Issue 25, 2012, Pages 4921-4928

  Smalberg, Jasper H ^a   Arends, Lidia R ^a,b   Valla, Dominique C ^c   Kiladjian, Jean Jacques ^d   Janssen, Harry L A ^a   Leebeek, Frank W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c BEAUJON HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

BUDD CHIARI SYNDROME; DIAGNOSTIC TEST; EXON; GENE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC SCREENING; HEMATOLOGIC DISEASE; HUMAN; JAK2V617F GENE; META ANALYSIS; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPLANCHNIC VEIN THROMBOSIS; VEIN THROMBOSIS;

EID: 84869053811     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-376517     Document Type: Review

References (74)

1. Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38(3):364-371. (Pubitemid 36286552)
2. Janssen HL, Wijnhoud A, Haagsma EB, et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut. 2001;49(5):720-724. (Pubitemid 32989212)
3. Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis. Prevalence, patient characteristics and lifetime risk: a population study based on 23 796 consecutive autopsies. World J Gastroenterol. 2006; 12(13):2115-2119.
4. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151(3):167-175.
5. Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004;39(2):500-508.
6. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31(3):587-591. (Pubitemid 30118625)
7. Mahmoud AE, Mendoza A, Meshikhes AN, et al. Clinical spectrum, investigations and treatment of Budd-Chiari syndrome. QJM. 1996;89(1):37-43. (Pubitemid 26023962)
8. Rajani R, Melin T, Bjornsson E, et al. Budd-Chiari syndrome in Sweden. Epidemiology, clinical characteristics and survival: an 18-year experience. Liver Int. 2009;29(2):253-259.
9. Smalberg JH, Darwish Murad S, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 2006; 91(12):1712-1713. (Pubitemid 46032973)
10. Bayraktar Y, Harmanci O, Buyukasik Y, et al. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci. 2008;53(10):2778-2783.
11. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51(1):210-218.
12. Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94(4):1063-1069.
13. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23(5):411-418. (Pubitemid 27501780)
14. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with Budd- Chiari syndrome. Ann Intern Med. 1985;103(3):329-334. (Pubitemid 15236564)
15. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13): 4272-4290. (Pubitemid 35429665)
16. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-1061. (Pubitemid 40386783)
17. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452-2466. (Pubitemid 44903749)
18. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-1148. (Pubitemid 40663494)
19. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17): 1779-1790. (Pubitemid 40570926)
20. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922-4929.
21. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5(1):55-61. (Pubitemid 44921067)
22. Janssen HL, Leebeek FW. JAK2 mutation: the best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? Hepatology. 2006; 44(6):1391-1393. (Pubitemid 44953641)
23. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108(10):3472-3476.
24. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270.
25. Scott LM, Beer PA, Bench AJ, Erber WN, Green AR. Prevalence of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol. 2007; 139(3):511-512. (Pubitemid 47512179)
26. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468. (Pubitemid 46193073)
27. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009; 6(11):627-637.
28. Bergamaschi GM, Primignani M, Barosi G, et al. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood. 2008;111(8):4418.
29. Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood. 2007; 110(7):2768-2769. (Pubitemid 47523205)
30. McCarthy N, McCarron SL, Langabeer SE, Prevalence of the JAK2 V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis. Acta Haematol. 2010;124(3):160-161.
31. Yoo EH, Jang JH, Park KJ, et al. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis. Int J Lab Hematol. 2011; 33(5):471-476.
32. Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2- V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood. 2006;108(9):3223-3224.
33. Goulding C, Uttenthal B, Foroni L, et al. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol. 2008;30(5):415-419.
34. Rossi D, Cresta S, Destro T, et al. JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia. Br J Haematol. 2007;138(6):813-814. (Pubitemid 47313208)
35. Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134(1):82-85.
36. Tondeur S, Boutruche S, Biron-Andreani C, Schved JF. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis: a 10-year retrospective study. Thromb Haemost. 2009;101(4):787-789.
37. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost. 2007;5(4):859-861. (Pubitemid 46563588)
38. Averbuch M, Aderka D, Winer Z, Levo Y. Budd- Chiari syndrome in Israel: predisposing factors, prognosis, and early identification of high-risk patients. J Clin Gastroenterol. 1991;13(3):321-324.
39. Brown KM, Kaplan MM, Donowitz M. Extrahepatic portal venous thrombosis: frequent recognition of associated diseases. J Clin Gastroenterol. 1985;7(2):153-159. (Pubitemid 15054345)
40. Cardin F, Graffeo M, McCormick PA, McIntyre N, Burroughs A. Adult "idiopathic" extrahepatic venous thrombosis: importance of putative "latent" myeloproliferative disorders and comparison with cases with known etiology. Dig Dis Sci. 1992; 37(3):335-339.
41. P'ng S, Carnley B, Baker R, Kontorinis N, Cheng W. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation. Clin Gastroenterol Hepatol. 2008;6(4):472-475.
42. Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007;102(11):2464-2470. (Pubitemid 47631782)
43. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005; 129(4):553-560. (Pubitemid 40769907)
44. Colaizzo D, Amitrano L, Iannaccone L, et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet. 2007;44(6):412-416. (Pubitemid 46953726)
45. De Stefano V, Fiorini A, Rossi E, et al. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. Hepatology. 2007;45(3):831-832; author reply 832-833.
46. Harmanci O, Ersoy O, Gurgey A, et al. The etiologic distribution of thrombophilic factors in chronic portal vein thrombosis. J Clin Gastroenterol. 2007;41(5):521-527. (Pubitemid 46642543)
47. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96(7):2364-2368.
48. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41(3):603-608. (Pubitemid 40289509)
49. Fiorini A, Chiusolo P, Rossi E, et al. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. Am J Hematol. 2009;84(2):126-127.
50. McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. Am J Clin Pathol. 2007;127(5):736-743.
51. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130(7):2031-2038. (Pubitemid 43816970)
52. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44(6):1528-1534. (Pubitemid 44953658)
53. Colaizzo D, Amitrano L, Tiscia GL, et al. Occurrence of the JAK2 V617F mutation in the Budd- Chiari syndrome. Blood Coagul Fibrinolysis. 2008;19(5):459-462.
54. Khuroo MS, Al-Suhabani H, Al-Sebayel M, et al. Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol. 2005;20(10): 1494-1502. (Pubitemid 43961101)
55. Kocher G, Himmelmann A. Portal vein thrombosis (PVT): a study of 20 non-cirrhotic cases. Swiss Med Wkly. 2005;135(25):372-376. (Pubitemid 41105182)
56. Orr DW, Patel RK, Lea NC, et al. Prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther. 2010;31(12):1330-1336.
57. Rajani R, Bjornsson E, Bergquist A, et al. The epidemiology and clinical features of portal vein thrombosis; a multicentre study. Aliment Pharmacol Ther. 2010;32(9):1154-1162.
58. Smira G, Gheorghe L, Iacob S, Coriu D, Gheorghe C. Budd Chiari syndrome and V617F/JAK 2 mutation linked with the myeloproliferative disorders. J Gastrointest Liver Dis. 2010;19(1):108-109.
59. Uskudar O, Akdogan M, Sasmaz N, Yilmaz S, Tola M, Sahin B. Etiology and portal vein thrombosis in Budd-Chiari syndrome. World J Gastroenterol. 2008;14(18):2858-2862.
60. Xavier SG, Gadelha T, Pimenta G, et al. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010;55(6):1770-1777.
61. Zahn A, Gotthardt D, Weiss KH, et al. Budd- Chiari syndrome: long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt. BMC Gastroenterol. 2010; 10:25.
62. Eapen CE, Velissaris D, Heydtmann M, Gunson B, Olliff S, Elias E. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut. 2006; 55(6):878-884. (Pubitemid 43764562)
63. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5(4):708-714. (Pubitemid 46563568)
64. Hoekstra J, Bresser EL, Smalberg JH, Spaander MC, Leebeek FW, Janssen HL. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost. 2011;9(11):2208-2214.
65. Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113(22):5617-5623.
66. Qi X, Yang Z, Bai M, Shi X, Han G, Fan D. Metaanalysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther. 2011;33(10):1087-1103.
67. Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol. 2011;31(3):485-493.
68. DeLeve LD, Valla DC, Garcia-Tsao G, et al. Vascular disorders of the liver. Hepatology. 2009; 49(5):1729-1764.
69. Aird WC. Vascular bed-specific thrombosis. J Thromb Haemost. 2007;5(suppl 1):283-291. (Pubitemid 46958844)
70. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246-5249.
71. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978; 2(8102):1219-1222. (Pubitemid 9071903)
72. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22(11):2020-2028.
73. Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Oncol Hematol. 1995;20(3):203-222.
74. Attwell A, Ludkowski M, Nash R, Kugelmas M. Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation. Aliment Pharmacol Ther. 2004;20(8):867-873. (Pubitemid 39424894)